Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chitosan oligosaccharide (COS) is a low molecular weight oligomer derived from the partial hydrolysis of chitosan, itself obtained by deacetylation of chitin. It consists of β-(1→4)-linked D-glucosamine and N-acetyl-D-glucosamine units, with an average molecular weight typically less than 5,000 Da[2][3]. Unlike high-molecular-weight chitosan, COS is highly water-soluble at neutral pH and exhibits improved bioavailability[3]. COS has been studied for a range of biological activities including anti-tumor, anti-inflammatory, antioxidant, antibacterial effects, immune modulation, and prebiotic activity[2][3][5][6]. Mechanistically, it can modulate inflammatory pathways (notably inhibiting NF-kappaB signaling), activate the calcium-sensing receptor (CaSR), and influence metabolic parameters such as body weight and blood glucose through effects on lipid metabolism and gut microbiota composition[5][6]. It is used in dietary supplements for cholesterol reduction and glucose control; it also finds applications in drug delivery systems due to its biocompatibility and biodegradability[3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chitosan oligosaccharide.